Lotus Pharmaceutical Co., Ltd. (TPE:1795)
Taiwan
· Delayed Price · Currency is TWD 222.00
-19.50 (-8.07%)
Mar 31, 2025, 1:35 PM CST
Lotus Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 18,584 | 16,958 | 14,633 | 12,649 | 10,729 | Upgrade
|
| Revenue Growth (YoY) | 9.59% | 15.89% | 15.68% | 17.90% | 11.63% | Upgrade
|
| Cost of Revenue | 7,660 | 7,574 | 6,827 | 7,009 | 6,132 | Upgrade
|
| Gross Profit | 10,924 | 9,384 | 7,806 | 5,640 | 4,597 | Upgrade
|
| Selling, General & Admin | 4,133 | 3,764 | 3,141 | 2,703 | 2,473 | Upgrade
|
| Research & Development | 613.9 | 541.46 | 419.01 | 373.84 | 384.14 | Upgrade
|
| Operating Expenses | 4,744 | 4,302 | 3,557 | 3,112 | 2,856 | Upgrade
|
| Operating Income | 6,180 | 5,082 | 4,249 | 2,529 | 1,740 | Upgrade
|
| Interest Expense | -561.39 | -533.69 | -356.22 | -266.69 | -304.45 | Upgrade
|
| Interest & Investment Income | 101.44 | 31.55 | 3.51 | 5.34 | 3.76 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | 3.78 | Upgrade
|
| Currency Exchange Gain (Loss) | 168.11 | 91.67 | -81.22 | -119.23 | 40.45 | Upgrade
|
| Other Non Operating Income (Expenses) | 28.84 | 23.94 | -10.31 | 1.78 | -9.4 | Upgrade
|
| EBT Excluding Unusual Items | 5,917 | 4,696 | 3,805 | 2,150 | 1,474 | Upgrade
|
| Gain (Loss) on Sale of Investments | 604.16 | 715.05 | 286.81 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.64 | -24.75 | 2.52 | -3.2 | -4.68 | Upgrade
|
| Asset Writedown | -159.99 | -179.37 | -138.26 | -233.18 | -127.68 | Upgrade
|
| Other Unusual Items | -0.91 | -103.79 | -16 | -43.42 | -40.31 | Upgrade
|
| Pretax Income | 6,360 | 5,103 | 3,940 | 1,870 | 1,302 | Upgrade
|
| Income Tax Expense | 1,294 | 997.3 | 919.46 | 466.65 | 274.58 | Upgrade
|
| Earnings From Continuing Operations | 5,066 | 4,106 | 3,021 | 1,403 | 1,027 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | -0.42 | Upgrade
|
| Net Income | 5,066 | 4,106 | 3,021 | 1,403 | 1,027 | Upgrade
|
| Net Income to Common | 5,066 | 4,106 | 3,021 | 1,403 | 1,027 | Upgrade
|
| Net Income Growth | 23.38% | 35.91% | 115.25% | 36.68% | 54.92% | Upgrade
|
| Shares Outstanding (Basic) | 262 | 261 | 261 | 255 | 243 | Upgrade
|
| Shares Outstanding (Diluted) | 263 | 262 | 262 | 257 | 243 | Upgrade
|
| Shares Change (YoY) | 0.53% | 0.13% | 1.95% | 5.43% | 0.65% | Upgrade
|
| EPS (Basic) | 19.35 | 15.72 | 11.59 | 5.50 | 4.22 | Upgrade
|
| EPS (Diluted) | 19.23 | 15.67 | 11.54 | 5.47 | 4.22 | Upgrade
|
| EPS Growth | 22.72% | 35.79% | 110.97% | 29.62% | 54.02% | Upgrade
|
| Free Cash Flow | 5,801 | 1,204 | 3,142 | -453.07 | 1,535 | Upgrade
|
| Free Cash Flow Per Share | 22.02 | 4.59 | 12.01 | -1.76 | 6.30 | Upgrade
|
| Dividend Per Share | 5.730 | 4.660 | 3.460 | 1.930 | 0.350 | Upgrade
|
| Dividend Growth | 22.96% | 34.68% | 79.27% | 451.43% | - | Upgrade
|
| Gross Margin | 58.78% | 55.34% | 53.35% | 44.59% | 42.84% | Upgrade
|
| Operating Margin | 33.25% | 29.97% | 29.04% | 19.99% | 16.22% | Upgrade
|
| Profit Margin | 27.26% | 24.21% | 20.64% | 11.09% | 9.57% | Upgrade
|
| Free Cash Flow Margin | 31.21% | 7.10% | 21.47% | -3.58% | 14.31% | Upgrade
|
| EBITDA | 7,331 | 6,171 | 5,094 | 3,204 | 2,365 | Upgrade
|
| EBITDA Margin | 39.45% | 36.39% | 34.81% | 25.33% | 22.04% | Upgrade
|
| D&A For EBITDA | 1,151 | 1,088 | 844.44 | 675.77 | 624.19 | Upgrade
|
| EBIT | 6,180 | 5,082 | 4,249 | 2,529 | 1,740 | Upgrade
|
| EBIT Margin | 33.25% | 29.97% | 29.04% | 19.99% | 16.22% | Upgrade
|
| Effective Tax Rate | 20.35% | 19.54% | 23.34% | 24.95% | 21.09% | Upgrade
|
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.